These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22023411)

  • 1. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery.
    Hack N; Akbar U; Thompson-Avila A; Fayad SM; Hastings EM; Moro E; Nestor K; Ward H; York M; Okun MS
    J Parkinsons Dis; 2014; 4(4):591-8. PubMed ID: 25035311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders in Parkinson's disease: prevalence and possible risk factors.
    Weintraub D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S110-3. PubMed ID: 20082968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compulsive behaviors in patients with Parkinson's disease.
    Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E
    Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S111-5. PubMed ID: 20123548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control and related disorders in Parkinson's disease.
    Weintraub D; Nirenberg MJ
    Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impulse control disorders in Parkinson's disease in a Chinese population.
    Fan W; Ding H; Ma J; Chan P
    Neurosci Lett; 2009 Nov; 465(1):6-9. PubMed ID: 19560522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic dysregulation syndrome in Parkinson's disease.
    Katzenschlager R
    J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
    Weintraub D; Koester J; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Arch Neurol; 2010 May; 67(5):589-95. PubMed ID: 20457959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.